IQVIA Holdings Inc. (IQV)
- Previous Close
229.20 - Open
230.92 - Bid 218.05 x 900
- Ask 245.89 x 800
- Day's Range
230.05 - 234.74 - 52 Week Range
167.42 - 261.73 - Volume
1,261,753 - Avg. Volume
937,283 - Market Cap (intraday)
42.649B - Beta (5Y Monthly) 1.53
- PE Ratio (TTM)
31.93 - EPS (TTM)
7.33 - Earnings Date Jul 30, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
271.24
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
www.iqvia.com87,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: IQV
Performance Overview: IQV
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IQV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IQV
Valuation Measures
Market Cap
42.65B
Enterprise Value
54.81B
Trailing P/E
31.98
Forward P/E
21.19
PEG Ratio (5yr expected)
1.33
Price/Sales (ttm)
2.88
Price/Book (mrq)
6.72
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
9.01%
Return on Assets (ttm)
5.03%
Return on Equity (ttm)
22.11%
Revenue (ttm)
15.07B
Net Income Avi to Common (ttm)
1.36B
Diluted EPS (ttm)
7.33
Balance Sheet and Cash Flow
Total Cash (mrq)
1.58B
Total Debt/Equity (mrq)
219.01%
Levered Free Cash Flow (ttm)
1.68B
Research Analysis: IQV
Company Insights: IQV
IQV does not have Company Insights